Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELND005 for Agitation and Aggression in Alzheimer's Disease
NCT01735630Phase 2Completed
- Sponsor
- OPKO Health
- Start
- Nov 2012
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of scyllo-inositol in Alzheimer's disease (AD), sponsored by OPKO Health. Started Nov 2012; status: completed.
02
Drugs
scyllo-inositol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01735630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01735630.